Insulin glargine and lixisenatide Subcutaneous and Pembrolizumab Intravenous
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Pembrolizumab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: pembrolizumab
Brand name: Keytruda
Synonyms: Pembrolizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Pemetrexed
- Insulin glargine and lixisenatide Subcutaneous-Pemetrexed Disodium
- Insulin glargine and lixisenatide Subcutaneous-Pemetrexed Intravenous
- Insulin glargine and lixisenatide Subcutaneous-Pemoline
- Insulin glargine and lixisenatide Subcutaneous-Penbutolol
- Insulin glargine and lixisenatide Subcutaneous-Penciclovir
- Pembrolizumab Intravenous-Insulin glargine, recombinant Subcutaneous
- Pembrolizumab Intravenous-Insulin glulisine
- Pembrolizumab Intravenous-Insulin Glulisine (Cartridges and Pens)
- Pembrolizumab Intravenous-Insulin Glulisine (Vials)
- Pembrolizumab Intravenous-Insulin glulisine Subcutaneous
- Pembrolizumab Intravenous-Insulin human inhaled Inhalation